Lv1
54 积分 2025-10-11 加入
Optimal Therapeutic Strategy for PD-L1 Negative Metastatic Non-Small Cell Lung Cancer: A Decision-Making Guide Based on Clinicopathological and Molecular Features
3个月前
已完结
Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves
3个月前
已完结
Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression
3个月前
已完结
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies
5个月前
已完结
Rearranged during transfection (RET) lung cancer – Update on targeted therapies
5个月前
已完结
AXL and c‐Met Dual‐Targeting in Non‐Small Cell Lung Cancer: A Review of Small‐Molecule Inhibitors and Their Structure–Activity Relationships
5个月前
已完结
Antibody–drug conjugates in lung cancer: current landscape and future perspectives
5个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
5个月前
已完结
Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer
5个月前
已完结
Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer
5个月前
已完结
皖公网安备34019202002308
